推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

[PDF] from leprahealthinaction.orgH SINGH, B NEL, V DEY, P TIWARI… - Leprosy …, 2011 - leprahealthinaction.org
... Lepr Rev (2011) 82, 17–24 0305-7518/11/064053+08 $1.00 q Lepra 17 Page 2. ... Exclusion criteria:
Those, who had taken any other medication during this study, Patients with any other chronic
illness Those who had interrupted the MDT medication Patient with lepra reaction ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgA MAGHANOY, I MALLARI, M BALAGON… - Leprosy …, 2011 - leprahealthinaction.org
... Lepr Rev (2011) 82, 65–69 0305-7518/11/064053+05 $1.00 q Lepra 65 ... Subjects were also
encouraged to report to the clinic between scheduled visits for unusual skin problems, including
Type 1 (reversal; RR) or Type 2 (erythema nodosum leprosum; ENL) lepra reactions. ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgD WEIAND, WC SMITH… - Leprosy review, 2011 - leprahealthinaction.org
... Lepr Rev (2011) 82, 70–73 70 0305-7518/11/064053+04 $1.00 q Lepra Page 2. ... FUNDING LEPRA,
the British Association of Dermatologists (BAD) and the University of Aberdeen's Alumni Annual
Fund all contributed towards the funding of this medical elective. ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgBLN Cards - Women, 2011 - leprahealthinaction.org
The following article, on the use of thalidomide in the treatment of leprosy, appeared in the WHO
Pharmaceuticals Newsletter, No. 2, 2003, and can be found on the WHO website (http://www.
who.int/ lep/TAG/Thal.doc). The article is followed by three commentaries on Dr ...
Related articles - View as HTML - All 4 versions
[PDF] from leprahealthinaction.orgP BHUSHAN, A AGGARWAL, R YADAV… - Leprosy …, 2011 - leprahealthinaction.org
... Correspondence to: Premanshu Bhushan, Skin Institute and School of Dermatology, N-block,
Greater Kailash-1, New Delhi-110048, India (e-mail: drpremanshu@gmail.com) Lepr Rev (2011)
82, 74–77 74 0305-7518/11/064053+04 $1.00 q Lepra Page 2. sought. ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgH SINGH, B NEL, V DEY, P TIWARI… - Leprosy …, 2011 - leprahealthinaction.org
... Lepr Rev (2011) 82, 17–24 0305-7518/11/064053+08 $1.00 q Lepra 17 Page 2. ... Exclusion criteria:
Those, who had taken any other medication during this study, Patients with any other chronic
illness Those who had interrupted the MDT medication Patient with lepra reaction ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgA MAGHANOY, I MALLARI, M BALAGON… - Leprosy …, 2011 - leprahealthinaction.org
... Lepr Rev (2011) 82, 65–69 0305-7518/11/064053+05 $1.00 q Lepra 65 ... Subjects were also
encouraged to report to the clinic between scheduled visits for unusual skin problems, including
Type 1 (reversal; RR) or Type 2 (erythema nodosum leprosum; ENL) lepra reactions. ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgD WEIAND, WC SMITH… - Leprosy review, 2011 - leprahealthinaction.org
... Lepr Rev (2011) 82, 70–73 70 0305-7518/11/064053+04 $1.00 q Lepra Page 2. ... FUNDING LEPRA,
the British Association of Dermatologists (BAD) and the University of Aberdeen's Alumni Annual
Fund all contributed towards the funding of this medical elective. ...
Related articles - View as HTML - All 3 versions
[PDF] from leprahealthinaction.orgBLN Cards - Women, 2011 - leprahealthinaction.org
The following article, on the use of thalidomide in the treatment of leprosy, appeared in the WHO
Pharmaceuticals Newsletter, No. 2, 2003, and can be found on the WHO website (http://www.
who.int/ lep/TAG/Thal.doc). The article is followed by three commentaries on Dr ...
Related articles - View as HTML - All 4 versions
[PDF] from leprahealthinaction.orgP BHUSHAN, A AGGARWAL, R YADAV… - Leprosy …, 2011 - leprahealthinaction.org
... Correspondence to: Premanshu Bhushan, Skin Institute and School of Dermatology, N-block,
Greater Kailash-1, New Delhi-110048, India (e-mail: drpremanshu@gmail.com) Lepr Rev (2011)
82, 74–77 74 0305-7518/11/064053+04 $1.00 q Lepra Page 2. sought. ...
Related articles - View as HTML - All 3 versions
DM Scollard, MV Chaduvula… - Clinical and Vaccine …, 2011 - Am Soc Microbiol
Type 1 reaction (T1R) is a systemic inflammatory syndrome causing substantial morbidity in
leprosy. T1R results from spontaneously enhanced cellular immunity in borderline types of
leprosy, but there are no established laboratory markers for the reaction. Preliminary ...
Related articles - All 3 versions
S Aggarwal, S Ali, R Chopra… - Journal of Infectious …, 2011 - jid.oxfordjournals.org
Methods. We investigated the association of 51 single-nucelotide polymorphisms (SNPs) in
anti-inflammatory cytokines (IL-10, TGFB1, IL-6, IL-4, and IL-13) and receptors (IL-10RA,
IL-10RB, TGFBR1, TGFBR2, IL-6R, IL-4R, IL-5RA, IL-5RB, and IL-13RA1) with ...
[PDF] from ufu.brMS Duthie, MN Hay, EM Rada, J Convit… - European Journal of …, 2011 - Springer
Abstract Although curable, leprosy requires better diagnostic and prognostic tools to
accompany therapeutic strategies. We evaluated the serum samples of leprosy patients from
Venezuela and Brazil for reactivity against the specific recombinant proteins, ML0405 and ...
Related articles - All 4 versions
A Alter, NT Huong, M Singh… - Journal of Infectious …, 2011 - jid.oxfordjournals.org
Experimental evidence suggested the existence of unidentified leprosy susceptibility loci in the
human leukocyte antigen (HLA) complex. To identify such genetic risk factors, a high-density
association scan of a 1.9-mega-base (Mb) region in the HLA complex was performed. ...
Cited by 4 - Related articles - All 4 versions
MLF Penna, JG Temporão, MAF Grossi… - … of Epidemiology and …, 2011 - jech.bmj.com
In 1997, without strong evidence, the WHO recommended the reduction of multibacillary
(MB) leprosy treatment from 24 to 12 months (it was rated grade D, evidence according to Oxford
Centre). This new disease duration reduction allowed the global elimination target to be ...
Related articles - All 3 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室